Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Paroxetine, drug interactions

Another practical example of a pharmacokinetic drug interaction concerns the incidence of seizures in patients given a standard (300 mg/ day) dose of clozapine. Should the patient be given an SSRI antidepressant (such as fluoxetine, fluvoxamine, sertraline or paroxetine) concurrently then the clearance of clozapine could be reduced by up to 50%, an effect which would be comparable with a doubling of the dose. This could lead to a threefold increase in the risk of the patient suffering a seizure. [Pg.94]

Venkatakrishnan, K and Obach, R.S. (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metabolism and Disposition ... [Pg.195]

Horrigan, J.P. and Barnhill, L.J. (1994) Paroxetine-pimozide drug interaction. / Am Acad Child Adolesc Psychiatry 33 1060-1061. [Pg.66]

Extrapyramidal side effects (EPS) associated with SSRI medications used as single agents were reported as early as 1979 (Meltzer et ah, 1979). Since then, several case reports have been published on use of fluoxetine (Elamilton and Opler, 1992), paroxetine (Nicholson, 1992), and sertraline (Opler 1994). The SSRI medications in combination with neuroleptics can cause severe EPS (Tate, 1989 Ketai, 1993) above and beyond what may be associated with increased levels of antipsychotic medications (Goff et ah, 1991), and are perhaps related to pharmacokinetic drug interactions. [Pg.276]

The major distinguishing characteristic among the SSRIs is CYP enzyme inhibition. Fluvoxamine, fluoxetine, and paroxetine produce substantial inhibition of one or more CYP enzymes, whereas citalopram and sertraline do not (Table 7-29). In fact, fluvoxamine, fluoxetine, and paroxetine have all caused fatal drug-drug interactions via such CYP enzyme inhibition (339, 496, 497). [Pg.155]

In comparison with TCAs, SSRIs cause fewer pharmacodynamic drug-drug interactions but some (i.e., fluvoxamine, fluoxetine, paroxetine) cause more CYP enzyme mediated pharmacokinetic drug-drug interactions. Unlike TCAs, SSRIs do not potentiate alcohol and perhaps even slightly antagonize its acute CNS effects. Nevertheless, there are some important adverse interactions. [Pg.156]

Fluoxetine and paroxetine are potent inhibitors of the CYP2D6 isoenzyme, and this contributes to potential drug interactions (see drug interactions). In contrast, fluvoxamine is an inhibitor of CYP3A4, whereas citalopram, escitalopram, and sertraline have more modest CYP interactions. [Pg.658]

FIGURE 7—54. Heroic combo 10 SSRI plus NRI. Here, 5HT and NE are both single-boosted. The preferred NRI is selective reboxetine, as there are no drug interactions. Nonselective TCAs that are preferential NRIs such as desipramine, maprotilene, nortriptyline, or protriptyline can be combined if plasma drug levels of the TCA are monitored, especially if fluoxetine or paroxetine is the SSRI chosen. [Pg.293]

Drug interactions Catecholamine-depleting drugs such as reserpine may have an additive effect in combination with betablockers. Drugs that inhibit CYP2D6 (quinidine, fluoxetine, paroxetine, and propafenone) increase metoprolol concentration. [Pg.488]

A meta-analysis of 20 short-term studies of five SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline) has been published (8). There were no overall differences in efficacy, but fluoxetine had a slower onset of action. Citalopram and sertraline were least likely to cause drug interactions, but citalopram was implicated more often in fatal overdoses. [Pg.53]

Carrier L. Donepezil and paroxetine possible drug interaction. J Am Geriatr Soc 1999 47(8) 1037. [Pg.639]

FLUOXETINE, FLUVOXAMINE, PAROXETINE BZDs - ALPRAZOLAM, DIAZEPAM, MIDAZOLAM t in plasma concentrations of these BZDs. Likely t sedation and interference with psychomotor activity Alprazolam, diazepam and midazolam are subject to metabolism by CYP3A4. Fluvoxamine, fluoxetine and possibly paroxetine are inhibitors of CYP3A4 sertraline is a weak inhibitor. SSRIs are relatively weak compared with ketoconazole, which is possibly 100 times more potent as an inhibitor Warn patients about risks associated with activities that require alertness. Consider use of alternatives such as oxazepam, lorazepam and temazepam, which are metabolized by glucuronidation >- For signs and symptoms of CNS depression, see Clinical Features of Some Adverse Drug Interactions, Central nervous system depression... [Pg.175]

Take care switching from or adding to SSRIs (especially fluoxetine or paroxetine) because of side effects due to the drug interaction... [Pg.325]


See other pages where Paroxetine, drug interactions is mentioned: [Pg.578]    [Pg.130]    [Pg.173]    [Pg.436]    [Pg.442]    [Pg.533]    [Pg.519]    [Pg.519]    [Pg.200]    [Pg.140]    [Pg.142]    [Pg.156]    [Pg.157]    [Pg.157]    [Pg.287]    [Pg.677]    [Pg.130]    [Pg.173]    [Pg.648]    [Pg.692]    [Pg.37]    [Pg.47]    [Pg.188]    [Pg.566]    [Pg.3110]    [Pg.3115]   
See also in sourсe #XX -- [ Pg.563 , Pg.576 , Pg.613 , Pg.1534 ]

See also in sourсe #XX -- [ Pg.79 , Pg.1165 , Pg.1228 , Pg.1229 , Pg.1246 ]




SEARCH



Paroxetine

Paroxetine interaction with other drugs

© 2024 chempedia.info